SLC5A2 and cancer: Given the limitations of the included quantitative systematic reviews, as well as imprecise effect estimates reported in these reviews, more long‐term data from high quality observational studies are needed to more precisely assess cancer risks associated with SGLT‐2 inhibitor use.